Literature DB >> 14747528

Dramatic effects of 2-bromo-5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole riboside on the genome structure, packaging, and egress of guinea pig cytomegalovirus.

Daniel E Nixon1, Michael A McVoy.   

Abstract

The halogenated benzimidazoles BDCRB (2-bromo-5,6-dichloro-1-beta-D-riborfuranosyl benzimidazole riboside) and TCRB (2,5,6-trichloro-1-beta-D-riborfuranosyl benzimidazole riboside) were the first compounds shown to inhibit cleavage and packaging of herpesvirus genomes. Both inhibit the formation of unit length human cytomegalovirus (HCMV) genomes by a poorly understood mechanism (M. R. Underwood et al., J. Virol. 72:717-715, 1998; P. M. Krosky et al., J. Virol. 72:4721-4728, 1998). Because the simple genome structure of guinea pig cytomegalovirus (GPCMV) provides a useful model for the study of herpesvirus DNA packaging, we investigated the effects of BDCRB on GPCMV. GPCMV proved to be sensitive to BDCRB (50% inhibitory concentration = 4.7 microM), although somewhat less so than HCMV. In striking contrast to HCMV, however, a dose of BDCRB sufficient to reduce GPCMV titers by 3 logs (50 microM) had no effect on the quantity of GPCMV genomic DNA that was formed in infected cells. Electron microscopy revealed that this DNA was in fact packaged within intranuclear capsids, but these capsids failed to egress from the nucleus and failed to protect the DNA from nuclease digestion. The terminal structure of genomes formed in the presence of BDCRB was also altered. Genomes with ends lacking a terminal repeat at the right end, which normally exist in an equimolar ratio with those having one copy of the repeat at the right end, were selectively eliminated by BDCRB treatment. At the left end, BDCRB treatment appeared to induce heterogeneous truncations such that 2.7 to 4.9 kb of left-end-terminal sequences were missing. These findings suggest that BDCRB induces premature cleavage events that result in truncated genomes packaged within capsids that are permeable to nuclease. Based on these and other observations, we propose a model for duplication of herpesvirus terminal repeats during the cleavage and packaging process that is similar to one proposed for bacteriophage T7 (Y. B. Chung, C. Nardone, and D. C. Hinkle, J. Mol. Biol. 216:939-948, 1990).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14747528      PMCID: PMC369448          DOI: 10.1128/jvi.78.4.1623-1635.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  66 in total

1.  Replication of the murine cytomegalovirus genome: structure and role of the termini in the generation and cleavage of concatenates.

Authors:  J R Marks; D H Spector
Journal:  Virology       Date:  1988-01       Impact factor: 3.616

2.  Biochemical studies of the maturation of herpesvirus nucleocapsid species.

Authors:  M L Perdue; J C Cohen; C C Randall; D J O'Callaghan
Journal:  Virology       Date:  1976-10-01       Impact factor: 3.616

3.  Structure and variability of the a sequence in the genome of human cytomegalovirus (Towne strain).

Authors:  E S Mocarski; A C Liu; R R Spaete
Journal:  J Gen Virol       Date:  1987-08       Impact factor: 3.891

4.  Herpes simplex virus amplicon: cleavage of concatemeric DNA is linked to packaging and involves amplification of the terminally reiterated a sequence.

Authors:  L P Deiss; N Frenkel
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

5.  Herpes simplex virus replicative concatemers contain L components in inverted orientation.

Authors:  D Bataille; A Epstein
Journal:  Virology       Date:  1994-09       Impact factor: 3.616

6.  Nucleotide sequences of the joint between the L and S segments of herpes simplex virus types 1 and 2.

Authors:  A J Davison; N M Wilkie
Journal:  J Gen Virol       Date:  1981-08       Impact factor: 3.891

7.  Structure of the heterogeneous L-S junction region of human cytomegalovirus strain AD169 DNA.

Authors:  J C Tamashiro; D Filpula; T Friedmann; D H Spector
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

8.  Specificity of cleavage in replicative-form DNA of bovine herpesvirus 1.

Authors:  W Hammerschmidt; H Ludwig; H J Buhk
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

9.  Isolation of human cytomegalovirus intranuclear capsids, characterization of their protein constituents, and demonstration that the B-capsid assembly protein is also abundant in noninfectious enveloped particles.

Authors:  A Irmiere; W Gibson
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

10.  The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress.

Authors:  Paula M Krosky; Moon-Chang Baek; Donald M Coen
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  8 in total

1.  The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase.

Authors:  Thomas Goldner; Guy Hewlett; Nicole Ettischer; Helga Ruebsamen-Schaeff; Holger Zimmermann; Peter Lischka
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

2.  Role of the UL25 protein in herpes simplex virus DNA encapsidation.

Authors:  Shelley K Cockrell; Minerva E Sanchez; Angela Erazo; Fred L Homa
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

3.  Mutational analysis of the herpes simplex virus type 1 DNA packaging protein UL33.

Authors:  Frauke Beilstein; Martin R Higgs; Nigel D Stow
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

Review 4.  Cytomegalovirus antivirals and development of improved animal models.

Authors:  Alistair McGregor; K Yeon Choi
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-09-01       Impact factor: 4.481

5.  Impact of 2-bromo-5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole riboside and inhibitors of DNA, RNA, and protein synthesis on human cytomegalovirus genome maturation.

Authors:  Michael A McVoy; Daniel E Nixon
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

6.  Susceptibilities of human cytomegalovirus clinical isolates and other herpesviruses to new acetylated, tetrahalogenated benzimidazole D-ribonucleosides.

Authors:  Jae-Seon Hwang; Rita Schilf; John C Drach; Leroy B Townsend; Elke Bogner
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

7.  Definition of the minimal cis-acting sequences necessary for genome maturation of the herpesvirus murine cytomegalovirus.

Authors:  Jian Ben Wang; Daniel E Nixon; Michael A McVoy
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

8.  A Guinea pig cytomegalovirus resistant to the DNA maturation inhibitor BDCRB.

Authors:  Amine Ourahmane; Anne Sauer; Daniel E Nixon; Christine Murphy; Melissa Mondello; Erin Douglass Chiu; Stephanie Siegmund; Jian Ben Wang; Michael A McVoy
Journal:  Antiviral Res       Date:  2018-04-09       Impact factor: 5.970

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.